Novel Immunotherapy Combos Show Promise in Stage III Non-Small Cell Lung Cancer
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
News
Latest News
Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
Digital Breast Tomosynthesis Tool Can Help Predict Breast Cancer
A DBT-based risk model can predict cancer after a negative screening exam, with high discriminative performance for one-year risk.
Eradication of H Pylori Infection Reduces Risk for Gastric Cancer
A team of researchers investigated the long-term effects of eliminating H pylori infection in patients at high risk for gastric cancer.
“Tragic Milestone”: One Million American Lives Lost to COVID-19
President Biden ordered U.S. flags to be flown at half-staff in honor of those lost.
GE Healthcare Contrast Media Products in Short Supply
A return to full stocking levels is expected by July 2022.
Ban of Indoor Tanning Beds Would Reduce Cancers, Cut Costs
The intervention would yield a net monetary benefit of £10.6 million and a net health benefit of 530 QALYs, researchers found.
FDA Issues Safety Alert for COVID-19 Test Over Concerns of False Results
In the safety communication, the FDA noted that the use of this unauthorized test may increase the risk of false results.
Improved Survival Supports Routine Use of Laparoscopic Surgery for Rectal Cancer
A meta-analysis showed a significant improvement in overall survival, but not disease-free survival, with laparoscopic surgery.
HER2-Low Should Not Be a Distinct Subtype of Breast Cancer, Researchers Say
There were no significant differences in outcomes between patients with low HER2 expression and those with no HER2 expression, after adjusting for hormone receptor status.
Recent Cancer Treatment Linked to Worse COVID-19 Outcomes
Cancer patients had higher risks for 30-day mortality and hospitalization.
HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Company Hid Problems With COVID-19 Vaccines From FDA
Nearly 400 million doses of vaccine made by Emergent were destroyed “due to poor quality control.”
Olumiant Approved for COVID-19 Treatment in Hospitalized Adults
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO Breast Cancer 2022
Loading... 
Loading...